Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.54 |
| ▸ | CNR2 | P34972 | 4/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 9/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23033606 | 0.83 | TRPV1 (0.47) | TRPV1CNR2CNR1MGLLDAGLA | |
| SCHEMBL4404110 | 0.77 | TRPV1 (0.59) | TRPV1CNR2CNR1MGLLDAGLA | |
| SCHEMBL4407129 | 0.77 | TRPV1 (0.86) | TRPV1CNR2CNR1MGLLDAGLA | |
| SCHEMBL4406015 | 0.77 | CNR2 (0.50) | TRPV1CNR2CNR1MGLLDAGLA | |
| SCHEMBL4411347 | 0.76 | TRPV1 (0.47) | TRPV1CNR2CNR1MGLLDAGLA | |
| SCHEMBL13183543 | 0.74 | PRMT6 (0.39) | TRPV1CNR2CNR1 | |
| SCHEMBL4407046 | 0.73 | TRPV1 (0.55) | TRPV1CNR2CNR1MGLLDAGLA | |
| SCHEMBL4409244 | 0.73 | HDAC6 (0.47) | TRPV1CNR2CNR1MGLLDAGLA | |
| SCHEMBL4408018 | 0.73 | TRPV1 (0.46) | TRPV1CNR2CNR1MGLLDAGLA | |
| SCHEMBL4404479 | 0.73 | TRPV1 (0.46) | TRPV1CNR2CNR1MGLLDAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785377-B2 | Tetrazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-1859782-B1 | Composition for coloring and/or lightening human hair comprising tetrazoles | HENKEL AG & CO KGAA (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20090130059-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | TRPV1 2551/4885CNR2 3630/4885CNR1 2611/4885 |
| US-20090130059-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | TRPV1 2551/4885CNR2 3630/4885CNR1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.